Humacyte, Inc. (NASDAQ:HUMA) Stock Has Average Target Price of $6.54

Key Points

• Analysts have a “Moderate Buy” consensus on Humacyte, with six buy ratings and one sell rating; the average 12-month price target is $6.54.
• HUMA opened at $0.53, near its 52-week low of $0.53, with shares down 2.6%. The company reported a quarterly loss of $0.16 per share and revenue of $0.41 million, both worse than analyst expectations.
• Institutional investors own 44.71% of Humacyte, with several firms—including Alyeska Investment Group—recently establishing new positions. The company’s lead product, Symvess, is FDA-approved for certain emergency vascular repairs.

Shares of Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $6.54.

Several brokerages recently issued reports on HUMA. Weiss Ratings reissued a "sell (e+)" rating on shares of Humacyte in a research note on Wednesday, July 8th. Benchmark dropped their price target on Humacyte from $2.00 to $1.00 and set a "speculative buy" rating for the company in a research note on Thursday, August 13th. HC Wainwright increased their price objective on shares of Humacyte from $3.00 to $4.00 and gave the company a "buy" rating in a report on Thursday, June 11th. Wall Street Zen cut shares of Humacyte from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $2.00 target price on shares of Humacyte in a report on Wednesday, August 12th.

Institutional Trading of Humacyte

A number of large investors have recently added to or reduced their stakes in the company. HBK Investments L P purchased a new stake in Humacyte during the second quarter valued at $617,000. Miramontes Capital LLC purchased a new position in shares of Humacyte in the 2nd quarter worth $85,000. Alyeska Investment Group L.P. bought a new stake in shares of Humacyte in the 2nd quarter worth about $4,700,000. Beacon Pointe Advisors LLC bought a new stake in shares of Humacyte in the 2nd quarter worth about $28,000. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Humacyte during the 2nd quarter valued at about $180,506. Institutional investors own 44.71% of the company's stock.

Humacyte Stock Down 2.6%

HUMA opened at $0.53 on Wednesday. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. The firm's fifty day moving average is $0.63 and its 200 day moving average is $0.79. The stock has a market cap of $147.98 million, a price-to-earnings ratio of -1.09 and a beta of 2.45. Humacyte has a fifty-two week low of $0.53 and a fifty-two week high of $2.55.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The business had revenue of $0.41 million during the quarter, compared to analysts' expectations of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. On average, sell-side analysts forecast that Humacyte will post -0.4 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc is a biotechnology company developing and commercializing off-the-shelf, bioengineered human tissues for use in vascular repair and regenerative medicine. Its technology is based on human acellular tissue-engineered vessels, which are designed to provide durable vascular conduits without requiring a patient-specific donor vessel.

The company's lead product, Symvess, is an acellular tissue-engineered vessel approved by the U.S. Food and Drug Administration for the treatment of extremity arterial injuries in adults when emergency vascular repair is needed and a suitable vein is unavailable or inappropriate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.